NCT03689972 · Interventional trial
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Overall registry status Completed
Phase 3
Conditions Multiple Sclerosis, Relapsing-Remitting
Delaware Valley sites
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory